Technological projects portfolio


Curative therapy for pulmonary arterial hypertension

Investment: €652k

Scope: Healthcare

Scientific field(s): Biology and medicinal chemistry

Institution(s): Université Paris-Saclay - CEA - CNRS - Inserm

Development: Start-up in progress/completed

#PAHT #TherapeuticInnovation #First-In-ClassCandidate


Pulmonary arterial hypertension (PAHT) is a rare and incurable pulmonary vascular disease. Patients usually live 3 to 5 years following diagnosis. The causes of PAHT are multifactorial. The increase in pulmonary pressure is due to the uncontrolled proliferation of vascular cells that obstruct the pulmonary vessels and lead to death by right heart failure.

The therapies currently available are essentially vasodilators that address the consequences of the disease and do nothing to slow its progression.

In the case of therapeutic failure, heart-lung transplant or double lung transplant is the last recourse, but it is only possible for 50% of patients.


A new first-in-class therapeutic target involved in the vascular remodeling that causes PAHT has been identified.

The NUTS-MAT project aims to develop molecules that are antagonistic to this target and “smart” (they don’t cross the blood-brain barrier), causing fewer side effects than traditional antagonists.

This innovative approach acts on the pulmonary vascular remodeling that causes PAHT.


The objective of the NUTS-MAT project is to position itself as a first-line treatment for pulmonary hypertension or as a supplement to current therapies, allowing patients to live with the illness long-term.